SCHEMBL1726879

SCHEMBL1726879

O=S(=O)(O)NC1CCCCCCC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.64
CA7 P43166 3/20 0.64
CA14 Q9ULX7 3/20 0.64
CA1 P00915 2/20 0.64
CA2 P00918 1/20 0.58
CA9 Q16790 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.46
KDM4E B2RXH2 2/20 0.46
RECQL P46063 1/20 0.46
EPHX1 P07099 5/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
MAPT P10636 1/20 0.44
EPHX2 P34913 1/20 0.44
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1727915 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL18585752 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
SCHEMBL1727205 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL6227 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL11686696 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
SCHEMBL1726858 1.00 CA12 (0.64) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL3723387 0.97 CA12 (0.61) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL4591944 0.97 CA12 (0.61) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL8532680 0.97 CA12 (0.61) CA12CA7CA14CA1CA2
Cyclamic Acid SCHEMBL120573 0.97 CA12 (0.61) CA12CA7CA14CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1204669-B1 TRICYCLIC MONOSACCHARIDE DERIVATIVES USEFUL IN TREATING ACUTE ISCHEMIA-INDUCED NEURODEGENERATION ORTHO MCNEIL PHARM INC (US) 2005-11-09 EP claimed
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2026-04-30 US disclosed
EP-4593631-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME Mars, Incorporated (US) 2025-08-06 EP disclosed
CN-119968127-A Animal food compositions with improved palatability and customizable properties and methods of making the same 玛氏公司 2025-05-09 CN disclosed
WO-2024073025-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-04 WO disclosed
EP-4344552-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-03 EP disclosed
US-8921124-B2 Pyrazole-based cyanine dye WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2014-12-30 US disclosed
WO-2012033298-A3 METHOD FOR MANUFACTURING A NOX GAS SENSOR, AND NOX GAS SENSOR MANUFACTURED USING SAME 일진머티리얼즈 주식회사 (KR) 2012-05-10 WO disclosed
EP-2006289-B1 PYRAZOLE-TYPE CYANINE DYE WAKO PURE CHEM IND LTD (JP) 2011-11-30 EP disclosed
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-03-12 US disclosed
EP-2006289-A1 PYRAZOLE-TYPE CYANINE DYE Wako Pure Chemical Industries, Ltd. (JP) 2008-12-24 EP disclosed
US-4260560-A HALOGENATING A SULFAMIC ACID IN PRESENCE OF PHOSPHORUS OR PHOSPHORUS TRIHALIDE BASF AKTIENGESELLSCHAFT (DE) 1981-04-07 US disclosed
US-4104298-A FROM SULFAMIC ACIDS AND PHOSPHORUS PENTAHALIDES BASF AKTIENGESELLSCHAFT (DE) 1978-08-01 US disclosed
US-4101571-A REACTING SULFAMIC ACIDS WITH PHOSGENE BASF AKTIENGESELLSCHAFT (DE) 1978-07-18 US disclosed
US-3992444-A BY REACTION OF A SULFAMIC ACID WITH AN ACID HALIDE BASF AKTIENGESELLSCHAFT (DT) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069546-A1 PYRAZOLE-BASED CYANINE DYE CBR3, CYB5R3, TST CA12 10/4885CA7 75/4885CA14 130/4885
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME PIGS, TAS2R13, CEL CA12 2472/4885CA7 1527/4885CA14 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.